学术探索
学术期刊
新闻热点
数据分析
智能评审

Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington's and Parkinson's diseases

被引：203
作者：
Bodner, RA
Outeiro, TF
Altmann, S
Maxwell, MM
Cho, SH
Hyman, BT
McLean, PJ
Young, AB
Housman, DE
Kazantsev, AG
机构：
[1] MIT, Ctr Canc Res, Cambridge, MA 02139 USA
[2] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Boston, MA 02129 USA
[3] Harvard Univ, Sch Med, Boston, MA 02129 USA
来源：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2006年 / 103卷 / 11期
关键词：
misfolded proteins; neuroclegenerative disease;
D O I：
10.1073/pnas.0511256103
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington's disease and alpha-synuclein in Parkinson's disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. One approach to the development of therapeutic intervention for these diseases has been to identify chemical compounds that reduce the size or number of inclusions. We have, however, identified a compound that promotes inclusion formation in cellular models of both Huntington's disease and Parkinson's disease. Of particular interest, this compound prevents huntingtin-mediated proteasome dysfunction and reduces a-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington's and Parkinson's diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding.
引用
收藏
页码：4246 / 4251
页数：6
相关论文
共 23 条
[1]   A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila [J].
Apostol, BL ;
Kazantsev, A ;
Raffioni, S ;
Illes, K ;
Pallos, J ;
Bodai, L ;
Slepko, N ;
Bear, JE ;
Gertler, FB ;
Hersch, S ;
Housman, DE ;
Marsh, JL ;
Thompson, LM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) :5950-5955
[2]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[3]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[4]   Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation [J].
Bennett, EJ ;
Bence, NF ;
Jayakumar, R ;
Kopito, RR .
MOLECULAR CELL, 2005, 17 (03) :351-365
[5]   Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases [J].
Bucciantini, M ;
Giannoni, E ;
Chiti, F ;
Baroni, F ;
Formigli, L ;
Zurdo, JS ;
Taddei, N ;
Ramponi, G ;
Dobson, CM ;
Stefani, M .
NATURE, 2002, 416 (6880) :507-511
[6]   Folding of newly translated proteins in vivo: The role of molecular chaperones [J].
Frydman, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :603-647
[7]   Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae [J].
Gilon, T ;
Chomsky, O ;
Kulka, RG .
EMBO JOURNAL, 1998, 17 (10) :2759-2766
[8]   The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction [J].
Glickman, MH ;
Ciechanover, A .
PHYSIOLOGICAL REVIEWS, 2002, 82 (02) :373-428
[9]   Inefficient degradation of truncated polyglutamine proteins by the proteasome [J].
Holmberg, CI ;
Staniszewski, KE ;
Mensah, KN ;
Matouschek, A ;
Morimoto, RI .
EMBO JOURNAL, 2004, 23 (21) :4307-4318
[10]   Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release [J].
Jana, NR ;
Zemskov, EA ;
Wang, GH ;
Nukina, N .
HUMAN MOLECULAR GENETICS, 2001, 10 (10) :1049-1059
123